Physician profile
Richard W Tim
NPI 1205868015
$2,581.46
in general payments reported to CMS, 2019-2025
45 companies · $66.56 in 2025
The $66.56 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,507 · 2020: $249 · 2021: $161 · 2022: $305 · 2023: $198 · 2024: $95.22 · 2025: $66.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $222.95 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $171.38 | 2019-2022 | |
| Merz North America, INC. | $150.91 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $144.69 | 2019 | |
| Abbvie INC. | $133.99 | 2022-2023 | Qulipta, Botox |
| Boston Scientific Corporation | $133.94 | 2019-2021 | |
| Ucb, INC. | $122.81 | 2019-2024 | Nayzilam, Rystiggo |
| Amgen INC. | $122.45 | 2019-2025 | Uplizna |
| Bausch Health US, LLC | $93.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $86.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $86.02 | 2019-2020 | |
| Assertio Therapeutics, INC. | $70.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $69.30 | 2019-2021 | |
| Biogen, INC. | $68.97 | 2019-2024 | Leqembi |
| Acorda Therapeutics, INC | $68.81 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.